TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2081685

Group type: EXPERIMENTAL
Intervention: Levamisole (150 or 200 mg once a week for 4 years)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (same schedule as levamisole)
Number of subjects: 41
Study: 763217

Group type: EXPERIMENTAL
Intervention: Actovegin (0.5 ml/kg/day for 14 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological saline solution (equivalent amounts)
Number of subjects: 40
Study: 30997153

Group type: EXPERIMENTAL
Intervention: PF-SZ-IFX/PF-SZ-IFX
Number of subjects: 650

Group type: COMPARATOR
Intervention: ref-IFX/ref-IFX
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: ref-IFX/PF-SZ-IFX
Number of subjects: 650
Study: 29119239

Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant 0.7 mg (DEX)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 259
Study: 26243249

Group type: EXPERIMENTAL
Intervention: Etanercept (10 mg) with bupivacaine (2 mL)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (bupivacaine [2 mL])
Number of subjects: 77
Study: 24556807

Group type: EXPERIMENTAL
Intervention: Internal attentional focus (counting coughs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: External attentional focus (counting tones)
Number of subjects: 24
Study: 22146946

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone and 5 mg tropisetron (group D+T)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 8 mg dexamethasone (group D)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 5 mg tropisetron (group T)
Number of subjects: 150
Study: 20875474

Group type: EXPERIMENTAL
Intervention: Scenarios with information on time gap till the next meal (1 hour or 4 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scenarios without information on time gap till the next meal (1 hour or 4 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Products perceived as fat, high in protein, savory taste, in one piece
Number of subjects: 0
Study: 17188417

Group type: EXPERIMENTAL
Intervention: Minimal training programme on using semiautomatic and fully automatic AEDs (15 min duration)
Number of subjects: 59
Study: 15059579

Group type: EXPERIMENTAL
Intervention: Interventional group (arterial embolization)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 12351298

Group type: EXPERIMENTAL
Intervention: Group Axillary
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group Humeral
Number of subjects: 100
Study: 9834207

Group type: EXPERIMENTAL
Intervention: G-CSF treatment (300 microg/m2 intravenously over 1 hour from day 1 of PBSCT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: G-CSF treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 7814826

Group type: EXPERIMENTAL
Intervention: mCPP (0.08 mg/kg over 2 min)
Number of subjects: 12
Study: 2536644

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 738
Study: 1106445

Group type: EXPERIMENTAL
Intervention: Erythromycin base (500 mg single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythromycin stearates (500 mg single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythromycin estolates (500 mg single dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythromycin base (250 mg every 6 hours for 4 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Erythromycin stearates (250 mg every 6 hours for 4 days)
Number of subjects: 10
Study: 31285661

Group type: EXPERIMENTAL
Intervention: Mailed HPV self-sampling kit
Number of subjects: 1052

Group type: COMPARATOR
Intervention: No additional communication (Control)
Number of subjects: 1052
Study: 28134628

Group type: EXPERIMENTAL
Intervention: LIPUS, 20 min/d
Number of subjects: 5983
Study: 26407963

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat Soft Mist Inhaler
Number of subjects: 200

Group type: COMPARATOR
Intervention: HandiHaler
Number of subjects: 200
Study: 25194940

Group type: EXPERIMENTAL
Intervention: Lower body strength + aerobic training (LBS-A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Upper body strength + aerobic training (UBS-A)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gross motor activities (GMA)
Number of subjects: 51
Study: 22189843

Group type: EXPERIMENTAL
Intervention: Benazepril plus amlodipine
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Benazepril plus hydrochlorothiazide
Number of subjects: 1414
Study: 19417602

Group type: EXPERIMENTAL
Intervention: Acceleromyography with preload
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acceleromyography without preload
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normalization of acceleromyographic TOF ratios
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normalization of both acceleromyography and mechanomyography
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acceleromyography and mechanomyography
Number of subjects: 60
Study: 17492896

Group type: EXPERIMENTAL
Intervention: Fampridine-SR
Number of subjects: 0
Study: 16388304

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (VivaStyle)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3.5% hydrogen peroxide (FKD)
Number of subjects: 6
Study: 12075201

Group type: EXPERIMENTAL
Intervention: Titanium bicortical screws
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biodegradable copolymer screws (poly‐L‐lactic acid 82% and polyglycolic acid 18%)
Number of subjects: 40
Study: 10321858

Group type: EXPERIMENTAL
Intervention: Clinic based interviews
Number of subjects: 210

Group type: COMPARATOR
Intervention: Self completion at home
Number of subjects: 210
Study: 8757422

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) at 375 mg and 250 mg b.i.d. for body weight > 60 and < or = 60 kg, respectively
Number of subjects: 159

Group type: COMPARATOR
Intervention: Zidovudine (AZT) maintaining the current dosage
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both groups (AZT and ddI)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Didanosine (ddI)
Number of subjects: 159
Study: 1914801

Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (1674 J/day or 400 cal/day of lean meat, fish, or fowl)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Balanced diet (4185-6277 J/day or 1000-1500 cal/day)
Number of subjects: 33
Study: 6884233

Group type: EXPERIMENTAL
Intervention: Oral hyposensitization (1,750,000 PNU, 3,500,000 NU)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Parenteral hyposensitization (1,550 PNU, 3,100 NU)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 31045817

Group type: EXPERIMENTAL
Intervention: Biportal technique/endoscopic surgery (BG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Microscopic surgery (OG)
Number of subjects: 70
Study: 28542506

Group type: EXPERIMENTAL
Intervention: Double Cash (DC)
Number of subjects: 3584

Group type: EXPERIMENTAL
Intervention: Fresh Food Voucher (FFV)
Number of subjects: 3584

Group type: EXPERIMENTAL
Intervention: Standard Cash (SC)
Number of subjects: 3584
Study: 25606785

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH, 20 IU/kg/dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: C1-inhibitor (C1-INH)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 23744509

Group type: EXPERIMENTAL
Intervention: Concomitant administration of HAV/MMRV/PCV-7 (Group 1)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Non-concomitant administration of HAV (Group 2)
Number of subjects: 653
Study: 21841997

Group type: EXPERIMENTAL
Intervention: Corticocancellous porcine bone graft
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (unfilled sockets)
Number of subjects: 15
Study: 19196110

Group type: EXPERIMENTAL
Intervention: Real phototherapy (3 J/cm(‐2))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo phototherapy (<.03 J/cm(‐3))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (cleaned and dressed with 1% silver sulfadiazine without phototherapy)
Number of subjects: 20
Study: 17598135

Group type: EXPERIMENTAL
Intervention: Solidex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duceram LFC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Artglass
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Targis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cervical regions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isthmus floor regions
Number of subjects: 60
Study: 15154663

Group type: EXPERIMENTAL
Intervention: PS76A2 (10, 30, or 70 ng mistletoe lectin per ml)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 11243947

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg, twice daily)
Number of subjects: 911

Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 911
Study: 9842405

Group type: EXPERIMENTAL
Intervention: Quinapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8092863

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 35

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 35
Study: 2525460

Group type: EXPERIMENTAL
Intervention: Turret nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inspiron nebulizer with albuterol (250, 250, 500, 1000 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Turret nebulizer with ipratropium bromide (50, 50, 100, 200 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inspiron nebulizer with ipratropium bromide (50, 50, 100, 200 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Turret nebulizer
Number of subjects: 8

Group type: COMPARATOR
Intervention: Inspiron nebulizer
Number of subjects: 8
Study: 31313243

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 14
Study: 31573612

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Doublets/bevacizumab
Number of subjects: 1187
Study: 28532872

Group type: EXPERIMENTAL
Intervention: AquaStretch
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Supervised Land Based Stretching (LBS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (normal physical activity)
Number of subjects: 29
Study: 25176615

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5mg daily
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Entecavir 0.5mg daily combined with tenofovir 300 mg
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: HBeAg-positive patients
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: HBeAg-negative patients
Number of subjects: 379
Study: 23350833

Group type: EXPERIMENTAL
Intervention: Fesoterodine (4 mg, with potential increase to 8 mg at week 4 or 8)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Fesoterodine
Number of subjects: 794

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794

Group type: COMPARATOR
Intervention: Fesoterodine and Placebo
Number of subjects: 794
Study: 21362359

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (intervention group, n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 61
Study: 20090354

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM) interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healing
Number of subjects: 0
Study: 16753387

Group type: EXPERIMENTAL
Intervention: High calcium diet (1,000 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low calcium diet (400 mg daily)
Number of subjects: 10
Study: 14749743

Group type: EXPERIMENTAL
Intervention: Elderberry juice (400 mg spray-dried powder containing 10% anthocyanes t.i.d. equivalent to 5 ml elderberry juice for 2 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single dose of elderberry juice (50 ml) along with a high-fat breakfast
Number of subjects: 40
Study: 11166743

Group type: EXPERIMENTAL
Intervention: Severe chorionic plate inflammation present in preterm deliveries (35.5%)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Amniochorionic‐decidual inflammation grades in preterm group: 31% severe (Grade 3‐4), 38% mild (Grade 1‐2), 31% none
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pathogenic bacteria isolated from patients with severe chorionic plate and/or chorioamnionic inflammation
Number of subjects: 82
Study: 9274279

Group type: EXPERIMENTAL
Intervention: Experimental pad variant 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Experimental pad variant 2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Experimental pad variant 3
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (previous pad variant)
Number of subjects: 20
Study: 7930250

Group type: EXPERIMENTAL
Intervention: Exercise treadmill testing with planar thallium-201 scintigraphy
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Thallium perfusion imaging
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Exercise test with or without thallium
Number of subjects: 936
Study: 2782945

Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3 (P2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3 (P3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Filtered air (FA) (P1)
Number of subjects: 40
Study: 55029

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin prophylaxis
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 112

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sodium and calcium heparin administered subcutaneously
Number of subjects: 112
Study: 28768700

Group type: EXPERIMENTAL
Intervention: Telematics support through Google Glass (GG) from an expert physician
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group receiving no assistance
Number of subjects: 72
Study: 26305649

Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acids (LCPUFAs) (1 g)
Number of subjects: 3741

Group type: EXPERIMENTAL
Intervention: Lutein (10 mg)/zeaxanthin (2 mg)
Number of subjects: 3741

Group type: COMPARATOR
Intervention: Placebo (no LCPUFAs)
Number of subjects: 3741

Group type: COMPARATOR
Intervention: Placebo (no lutein/zeaxanthin)
Number of subjects: 3741
Study: 23442574

Group type: EXPERIMENTAL
Intervention: Online only group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Online and face-to-face group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 180
Study: 22054797

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (400-800 mg once daily)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 19553452

Group type: EXPERIMENTAL
Intervention: Cholinergic stimulation with physostigmine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo with saline
Number of subjects: 22
Study: 17976095

Group type: EXPERIMENTAL
Intervention: Right ventricle to pulmonary artery shunt (RV-PA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Modified Blalock‐Taussig shunt (BTS)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (BTS and RV-PA)
Number of subjects: 82
Study: 14998068

Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 4499

Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 4499

Group type: COMPARATOR
Intervention: Rizatriptan 10 mg
Number of subjects: 4499

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 4499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4499
Study: 10997497

Group type: EXPERIMENTAL
Intervention: Penciclovir 1% cream applied 5 times daily for up to 7 days
Number of subjects: 205

Group type: COMPARATOR
Intervention: Acyclovir 3% cream
Number of subjects: 205
Study: 9115549

Group type: EXPERIMENTAL
Intervention: Intraoperative isometry measurements (group I)
Number of subjects: 94

Group type: COMPARATOR
Intervention: No intraoperative isometry measurements (group II)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall failure rate in group I
Number of subjects: 94

Group type: COMPARATOR
Intervention: Overall failure rate in group II
Number of subjects: 94
Study: 1484177

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day for 8 weeks)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Sertraline (50, 100, or 200 mg/day for 12 weeks)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study: 6382103

Group type: EXPERIMENTAL
Intervention: Doxium (calcium dobesilate) 1,500 mg daily for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31250356

Group type: EXPERIMENTAL
Intervention: Broccoli sprout supplementation (15 capsules daily containing 90 mg sulforaphane and 180 mg glucoraphanin)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (methylcellulose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Broccoli sprout supplementation
Number of subjects: 40
Study: 30439359

Group type: EXPERIMENTAL
Intervention: NOMAC + E2 (700μg)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: NOMAC + E2 (900μg)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: ENG + E2 (100μg)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: ENG + E2 (125μg)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 28476266

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 432
Study: 27340991

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injections (16 mg/mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 24
Study: 25403207

Group type: EXPERIMENTAL
Intervention: Extended rituximab exposure (375 mg/m²) with 6×R‐CHOP‐14 (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone on a 14-day schedule)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Extended rituximab exposure in poor-prognosis patients
Number of subjects: 189

Group type: COMPARATOR
Intervention: RICOVER-60 trial (control group with 6×R‐CHOP‐14 plus eight 2-week applications of rituximab)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Comparison of outcomes between SMARTE-R-CHOP-14 and RICOVER-60
Number of subjects: 189
Study: 22522725

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (n = 24)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Usual care (n = 22)
Number of subjects: 683
Study: 19244175

Group type: EXPERIMENTAL
Intervention: Selenium (200 microg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of Selenium and Vitamin E
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 39
Study: 17346324

Group type: EXPERIMENTAL
Intervention: Postoperative education and telephone interview on the second postoperative day
Number of subjects: 234

Group type: COMPARATOR
Intervention: Usual routine information (Control)
Number of subjects: 234
Study: 15115902

Group type: EXPERIMENTAL
Intervention: High doses of bimakalim (0.1, 0.3 or 0.6 mg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Low doses of bimakalim (0.025 or 0.05 mg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Bimakalim (both high and low doses)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 11641896

Group type: EXPERIMENTAL
Intervention: Ethanol consumption (1 gram per kg of body weight)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no ethanol consumption)
Number of subjects: 29
Study: 9853633

Group type: EXPERIMENTAL
Intervention: KP model (consultation focused on selected high-risk ambulatory care patients)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: KP model
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: State model (consultation about new or changed prescriptions)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control model
Number of subjects: 6000
Study: 7865090

Group type: EXPERIMENTAL
Intervention: 0.15% triclosan
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.1% triclosan with 1.5% SLS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.05% triclosan with 0.25% SLS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan (topical application)
Number of subjects: 8
Study: 2573298

Group type: EXPERIMENTAL
Intervention: Procaterol high dose (0.01 mg/inhalation, two inhalations, three times daily)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Procaterol low dose (0.01 mg/inhalation, one inhalation, three times daily)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 4605401

Group type: EXPERIMENTAL
Intervention: A2/HK/68 vaccine
Number of subjects: 18524

Group type: COMPARATOR
Intervention: B/Mass/66 vaccine
Number of subjects: 18524

Group type: COMPARATOR
Intervention: Bivalent vaccine (B/Mass/66 and A2/Mtl/68)
Number of subjects: 18524

Group type: COMPARATOR
Intervention: Standard aqueous killed bivalent vaccine
Number of subjects: 18524

Group type: COMPARATOR
Intervention: Zonally-purified vaccines
Number of subjects: 18524
Study: 31000205

Group type: EXPERIMENTAL
Intervention: 2-dimensional treatment planning
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 3-dimensional treatment planning
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cephalometric measurement of accuracy in the anterior maxilla
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL)
Number of subjects: 57
Study: 28764729

Group type: EXPERIMENTAL
Intervention: NWpG‐IC
Number of subjects: 511

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 511
Study: 26374833

Group type: EXPERIMENTAL
Intervention: Ketoacid supplementation (12 tablets per day)
Number of subjects: 100